ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01405118
Recruitment Status : Completed
First Posted : July 29, 2011
Last Update Posted : August 18, 2011
Sponsor:
Information provided by:
Pfizer

Brief Summary:
This study will evaluate the potential effect of CP 690,550 on the pharmacokinetics of metformin, a probe drug for organic cationic transport.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: Metformin/CP-690,550 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, Open Labeled, Fixed Sequence Study To Estimate The Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers
Study Start Date : June 2011
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Metformin/CP-690,550 Drug: Metformin/CP-690,550
Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.



Primary Outcome Measures :
  1. AUCinf (Area under the plasma concentration-time profile from time zero extrapolated to infinite time) of metformin [ Time Frame: 0.5, 1.5, 2, 3, 4, 6, 8, 9, 10, 12 and 24 hours after the metformin dose on Day 4 ]
  2. Cmax (Maximum plasma concentration) of metformin [ Time Frame: 0.5, 1.5, 2, 3, 4, 6, 8, 9, 10, 12 and 24 hours after the metformin dose on Day 4 ]
  3. Clr (Renal clearance) of metformin [ Time Frame: 0.5, 1.5, 2, 3, 4, 6, 8, 9, 10, 12 and 24 hours after the metformin dose on Day 4 ]

Secondary Outcome Measures :
  1. AUClast (Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration) of metformin [ Time Frame: 0.5, 1.5, 2, 3, 4, 6, 8, 9, 10, 12 and 24 hours after the metformin dose on Day 4 ]
  2. t½ (Terminal half-life) of metformin [ Time Frame: 0.5, 1.5, 2, 3, 4, 6, 8, 9, 10, 12 and 24 hours after the metformin dose on Day 4 ]
  3. Tmax (Time for maximum plasma concentration) of metformin [ Time Frame: 0.5, 1.5, 2, 3, 4, 6, 8, 9, 10, 12 and 24 hours after the metformin dose on Day 4 ]
  4. Ae24 (Cumulative amount of drug recovered unchanged in urine from time zero to 24 hours postdose) of metformin [ Time Frame: 0 hours and intervals 0-3, 3-6, 6-9, 9-12 and 12 24 hours after the metformin dose on Day 4 ]
  5. Ae24% (Percent of dose recovered unchanged in urine from time zero to 24 hours postdose) of metformin [ Time Frame: 0 hours and intervals 0-3, 3-6, 6-9, 9-12 and 12 24 hours after the metformin dose on Day 4 ]
  6. Clr (Renal clearance) over each collection interval for metformin [ Time Frame: 0 hours and intervals 0-3, 3-6, 6-9, 9-12 and 12 24 hours after the metformin dose on Day 4 ]
  7. CP-690,550 plasma concentration at 2 hours postdose [ Time Frame: 2 hrs after first CP-690,550 dose on Day 4 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adult healthy male and/or female (of non child bearing potential) subjects.

Exclusion Criteria:

  • Subjects with clinically significant systemic and laboratory abnormalities.
  • Subjects with clinically significant infections within the past 3 months.
  • Women of child-bearing potential.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01405118


Locations
Belgium
Pfizer Investigational Site
Bruxelles, Belgium, B-1070
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT01405118     History of Changes
Other Study ID Numbers: A3921143
First Posted: July 29, 2011    Key Record Dates
Last Update Posted: August 18, 2011
Last Verified: August 2011

Keywords provided by Pfizer:
Drug-Drug Interaction Healthy Volunteers CP-690
550 Metformin

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Metformin
Tofacitinib
Hypoglycemic Agents
Physiological Effects of Drugs
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action